Clinical trials: Antiviral Treatment
Chronic Hepatitis c Genotype 1
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1.
- Trial name
- NCT04246723
- Testing
- Narlaprevir, Ritonavir, Sofosbuvir
- Where
- 5 sites in Russia
- Volunteers
- 85 people
- Sponsor
- R-Pharm
Hepatitis C, Chronic
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®)…
- Trial name
- NCT01271790
- Testing
- Tegobuvir (GS-9190), GS-9451, Pegasys®
- Where
- 144 sites in United States, Austria and 6 more
- Volunteers
- 245 people
- Sponsor
- Gilead Sciences
HIV Infection
Early Antiviral Therapy for Critically Ill HIV Infected Patients
The aim of the study is to verify the effect of HAART in critically ill HIV infected patients. The current practice is to begin antiviral therapy after ICU discharge, when the condition of the patient is more stable.
- Trial name
- NCT01455688
- Testing
- early HAART, Late HAART
- Where
- Brazil
- Volunteers
- 115 people
- Sponsor
- Hospital Nossa Senhora da Conceicao
Chronic Hepatitis C
Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir
The purpose of the study is to 1- detect and quantify HCV-PI resistant mutants with ultra-deep pyrosequencing (UDPS) technology, 2 - detect SNPs in P-glyocoprotein and CYP3A genes, in HCV mono-infected patients under/after…
- Trial name
- GENUPI (NCT01577069)
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Association HGE CHU Bordeaux Sud
Chronic Hepatitis B
Prospective Observational Cohort Study for the Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B
The aim of this study is to investigate the off-treatment sustained virological and biochemical response in chronic hepatitis B patients following the guideline by the Asian Pacific Association for the Study of the Liver (APASL)…
- Trial name
- NCT01533051
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Covid19
Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients
The phase II clinical trial, with three arms and at rate of 10 patients per arm, received the approval of the National Committee for Ethics and Health Research.
- Trial name
- CANCOVID-19 (NCT04502342)
- Testing
- Hydroxycloroquine and Azythromycine, Cospherunate/Azythromycine, Cospherunate/Phytomedicine/Azythromycien
- Where
- Guinea
- Volunteers
- 30 people
- Sponsor
- Institute for Research and Development of Medicinal and Food Plants of Guinea
Chronic Hepatitis c
Long Term Follow up of Chronic HCV Patients Receiving DAAS
Follow up of Chronic hepatitis C Patients with moderate to severe fibrosis and cirrhosis treated with Direct Acting Antivirals after Sustained Virological Response for 4-5 years to detect changes in hepatic fibrosis and liver…
- Trial name
- NCT05170490
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Human Immunodeficiency Virus, Disorder of Immune Reconstitution
Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
HIV-1 infection is characterized by progressive depletion of CD4+ T cells that eventually leads to clinically significant immunodeficiency.
- Trial name
- NCT01213186
- Testing
- high dose of MSC, low dose of MSC treatment
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Fu-Sheng Wang
Hepatitis B Reactivation, Hematopoietic Stem Cell Transplantation
Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
This study is a randomized, prospective, comparative study of the effectiveness of prophylactic entecavir treatment for HBV reactivation in past HBV infected patients (HBsAg-, HBcIgG+) with allogeneic hematopoietic stem cell…
- Conditions
- Hepatitis B Reactivation, Hematopoietic Stem Cell Transplantation, Antiviral Drug, HBV
- Trial name
- NCT04942886
- Testing
- Baracle Tab.®
- Where
- South Korea
- Volunteers
- 226 people
- Sponsor
- Seoul St. Mary's Hospital
Chronic Hepatitis C (Disorder)
Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs
Recently,surprisingly and unexpectedly increased aggressiveness and high rates of HCC recurrence (28%(16/58) and 29%(17/59), respectively) have been reported in patients who cleared HCV with DAAs after achieving a complete…
- Trial name
- NCT03063723
- Testing
- Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C, Chronic
Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in…
- Trial name
- NCT01439373
- Testing
- GSK2336805, Pegylated interferon alfa-2a, Ribavirin
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis
Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
The current study is a prospective, randomized, open, multi-center investigation. The aim of the study is to investigate whether the HBeAg seroconversion rate can be improved if applying combination therapy in HBeAg positive CHB…
- Trial name
- NCT03013556
- Testing
- Group A, TDF, Group B:TDF then TDF and Peginterferon alfa-2a, Group C:TDF and Peginterferon alfa-2a then TDF
- Where
- 8 sites in China
- Volunteers
- 180 people
- Sponsor
- Ruijin Hospital
Hepatocellular Carcinoma
Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, its survival rate ranks only second to lung cancer and it is a severe threat to human health. In Egypt, HCC constitutes a significant public health problem.
- Trial name
- NCT04220151
- Testing
- DNA methylation
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
HIV Infections
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children
To evaluate the safety and determine the pharmacokinetic disposition of stavudine (d4T) alone and in combination with didanosine (ddI), and whether concurrent administration alters the disposition of either drug.
- Trial name
- NCT00000851
- Testing
- Stavudine, Didanosine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 198 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bioequivalence
Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting…
- Trial name
- Favipiravir (NCT04406194)
- Testing
- FAVICOVIR 200 mg Film Tablet, AVIGAN 200 mg Film Tablets
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Atabay Kimya Sanayi Ticaret A.S.
Chronic Infection
Orange Juice Consumption in Patients With Hepatitis C
This study aimed to verify whether orange juice, source of citrus flavonoids and vitamin C, may contribute to the treatment of patients with chronic hepatitis C.
- Trial name
- NCT03026569
- Testing
- Orange juice (500 mL/d)
- Where
- Brazil
- Volunteers
- 43 people
- Sponsor
- São Paulo State University
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Sarcoma, Kaposi, HIV Infections
A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma
To determine the toxicity and response to treatment with cytotoxic chemotherapy using doxorubicin (Adriamycin), bleomycin, and vincristine (DBV) for advanced AIDS-related Kaposi's sarcoma in combination with either didanosine…
- Trial name
- NCT00000954
- Testing
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
The primary purpose of this study is to assess the antiviral activity of VH3739937 in Human Immunodeficiency Virus Type-1 (HIV-1) infected treatment naive (TN) participants during monotherapy.
- Trial name
- NCT06061081
- Testing
- VH3739937
- Where
- 18 sites in United States, Argentina and 4 more
- Volunteers
- 21 people
- Sponsor
- ViiV Healthcare
Hepatitis C
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
To demonstrate the effectiveness of DCV 3DAA fixed dose regimen in treatment naive and treatment experienced non-cirrhotic subjects
- Trial name
- NCT01979939
- Testing
- DCV/ASV/BMS-791325
- Where
- 66 sites in United States, Australia and 3 more
- Volunteers
- 416 people
- Sponsor
- Bristol-Myers Squibb